Cytomx Therapeutics, INC 8-K filings

CytomX Therapeutics reported Q2 2026 financial results, highlighting progress in its Varseta-M program, expansion of its Regeneron collaboration, and strengthening of its leadership team, while also noting increased operating expenses and decreased revenue.

CytomX Therapeutics, Inc. announced the immediate appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors.

CytomX Therapeutics and Regeneron Pharmaceuticals have amended their collaboration agreement to extend program selection and add up to eight new cancer therapy programs, with potential milestones reaching $4 billion.

CytomX Therapeutics announced its 2025 financial results and provided updates on its clinical-stage oncology programs, Varseta-M and CX-801.

CytomX Therapeutics announced its third quarter 2025 financial results and provided updates on its oncology pipeline, including progress for CX-2051 and CX-801.

CytomX Therapeutics provided an update on its CX-2051 Phase 1 study, noting a Grade 5 adverse event but confirming continued study execution and enrollment.

CytomX Therapeutics announced its second quarter 2025 financial results, highlighted by positive interim clinical data for CX-2051 in advanced colorectal cancer and a successful $100 million stock offering.

CytomX Therapeutics, Inc. announced that its stockholders approved an amended and restated 2015 Equity Incentive Plan, increasing the available share pool for employee compensation, alongside other routine corporate governance proposals at its 2025 Annual Meeting.

CytomX Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter of potential delisting.

CytomX Therapeutics successfully closes a public offering of common stock, raising approximately $93.4 million for research and development and general corporate purposes.

CytomX Therapeutics reports encouraging interim Phase 1 data for CX-2051 in advanced colorectal cancer and details its Q1 2025 financial performance, extending its cash runway into Q2 2026.

CytomX Therapeutics reports 2024 financial results, highlighting progress with CX-2051 and CX-801, and extends cash runway into Q2 2026 through cost reductions.

CytomX Therapeutics has received a notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share.

CytomX Therapeutics reports the departure of Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, effective February 7, 2025.

CytomX Therapeutics will restructure its business, reducing its workforce by approximately 40% to prioritize key programs and extend its cash runway into the second quarter of 2026.

CytomX Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical pipeline, including progress in dose escalation for multiple cancer therapies.

CytomX Therapeutics announced its second quarter 2024 financial results, highlighting progress in its clinical programs and partnerships.

CytomX Therapeutics has promoted Chris Ogden to Chief Financial Officer, effective June 15, 2024, with associated stock and restricted stock unit awards.

CytomX Therapeutics successfully increased its authorized common stock shares to 300 million and elected new directors at its 2024 Annual Meeting.

CytomX Therapeutics reports encouraging initial safety and efficacy data from its Phase 1a trial of CX-904, a novel T-cell engager, showing promising results in advanced pancreatic cancer.

CytomX Therapeutics reported positive initial Phase 1a data for its CX-904 T-cell engager, along with other pipeline advancements and financial results for the first quarter of 2024.

CytomX Therapeutics has appointed Zhen Su, M.D., M.B.A., to its Board of Directors and adopted amended and restated bylaws to modernize certain procedures.

CytomX Therapeutics announced its 2023 financial results, highlighting progress in its pipeline and strategic collaborations, while also noting the discontinuation of one partnered program.